Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma

Cancer

Volumn 88, Issue 6, 2000, Pages 1432-1437

  Abendstein, Burghard ^a   Marth, Christian ^a   Müller Holzner, Elisabeth ^a   Widschwendter, Martin ^a   Daxenbichler, Günter ^a   Zeimet, Alain G ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

Ascites; Autoantibodies; Ovarian carcinoma; P53; Prognosis

Indexed keywords

AUTOANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; ASCITES FLUID; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SERUM; TISSUE DISTRIBUTION;

ADULT; AGED; ANALYSIS OF VARIANCE; ASCITES; AUTOANTIBODIES; CARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORECASTING; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034654347     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000315)88:6<1432::AID-CNCR22>3.0.CO;2-8     Document Type: Article

References (34)

1. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17:43-52.
2. Levine AJ. The p53 protein and its interaction with the oncogene products of small DNA tumor viruses. Virology 1990;177:419-26.
3. Lane DP. p53, guardian of the genome. Nature 1992;358: 15-6.
4. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51:2979-84.
5. Goff BA, Shy K, Geer BE, Muntz HG, Skelly M, Gown AM. Overexpression and relationships of HER-2/neu, epidermal growth factor receptor, p53, Ki-67 and tumor necrosis factor alpha in epithelial ovarian cancer. Eur J Gynaecol Oncol 1996;17:487-92.
6. Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, et al. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol 1999;72:76-81.
7. Kupryjanczyk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A 1993;90:4961-5.
8. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
9. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. bcl-2 expression, p53 accumulation and apoptosis in ovarian carcinomas. Am J Clin Pathol 1996;105: 341-9.
10. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
11. Henriksen R, Strang P, Wilander E, Backstrom T, Tribukait B, Oberg K. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 1994;53:301-6.
12. Green JA, Robertson LJ, Campbell IR, Jenkins J. Expression of p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 1995;19:151-5.
13. Vasey PA, Jones NA, Jenkins S, Dive C, Rown R. Cisplatin, camptothecin and taxol sensitivities of cells with p53 associated multidrug resistance. Mol Pharmacol 1996;50:1536-40.
14. Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997;75:230-5.
15. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera of patients with breast cancer. Int J Cancer 1982;30:403-8.
16. Labrecque AJ, Naor N, Thomson G, Matlashewski G. Analysis of anti-p53 antibody response in cancer patients. Cancer Res 1993;53:3468-71.
17. Schlichtholz B, Legros Y, Gillet D, Guillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-4.
18. Marxsen J, Schmiegel W, Roder C, Harder R, Juhl H, Henne-Bruns D, et al. Detection of the p53-antibody response in malignant and benign pancreatic disease. Br J Cancer 1994; 70:1031-4.
19. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994;58:480-7.
20. Angelopoulou K, Diamandis EP. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur J Cancer 1997;33:115-21.
21. Tropé C, Andersson H, Björkholm E, Frankendal B, Himmelman A, Högberg T, et al. Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer. Acta Oncol 1997;35:109-18.
22. Schöndorf T, Engel H, Lindemann C, Kohlhagen H, von Rücker AA, Mallmann P. Cellular characteristics of peripheral blood lymphocytes and tumor-infiltrating lymphocytes in patients with gynaecological tumours. Cancer Immunol Immunother 1997;44:88-96.
23. Schildkraut JM, Bastos E, Berchuck A. Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 1997;89:932-8.
24. Lubin R, Schlichtholz B, Bengoufa D, Zalcman G, Tredaniel J, Hirsch A, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1992;53:5872-6.
25. Gadducci A, Ferdeghini M, Buttitta F, Fanucchi A, Annicchiarico C, Prontera C, et al. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. Anticancer Res 1996;16:3519-24.
26. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 1996;93:14094-9.
27. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997;57:870-4.
28. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994;69:1115-9.
29. Werner JA, Gottschlich S, Folz BJ, Goeroegh T, Lippert BM, Maass JD, et al. p53 serum antibodies as prognostic indicator in head and neck cancer. Cancer Immunol Immunother 1997;44:112-6.
30. Houbiers JG, van der Burg SH, van de Watering LM, Tollenaar RA, Brand A, van de Velde CJ, et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. Br J Cancer 1995;72:637-41.
31. Maehara Y, Kakeji Y, Watanabe A, Baba H, Kusumoto H, Kohnoe S, et al. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999; 85:302-8.
32. Mantovani A. Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest 1994;71:5-16.
33. Marth C, Weger A, Müller-Holzner E, Zeimet AG, Moncayo-Naveda H, Daxenbichler G, et al. The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur J Cancer 1993;29A:1863-8.
34. Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Müller-Holzner E, et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998;16:1861-8.